Business UpdateMay 28, 2026, 11:11 AM
Medinotec Details Business, Strategy, FDA Clearances
AI Summary
Medinotec Inc. provided a comprehensive business update in its 10-K filing, detailing its operations as a medical device manufacturer and distributor. The company highlighted its proprietary products, including the Trachealator and Outflo Aortic Valve Dilation Balloon Catheter, both of which have received FDA 510(k) clearance. Medinotec is focused on expanding its product portfolio, developing internal capabilities, and evaluating strategic acquisitions, while managing a global distribution network across approximately 45 countries. The company reported US sales of $611,860 in fiscal 2026 and a decrease in compliance costs, but also noted an impairment allowance against a $750,000 receivable.
Key Highlights
- Medinotec's Trachealator received FDA 510(k) clearance in November 2021.
- Outflo Aortic Valve Dilation Balloon Catheter received FDA 510(k) clearance in March 2025.
- US sales were $611,860 in fiscal 2026, representing 6% of total sales.
- US sales were $678,105 in fiscal 2025, representing 7% of total sales.
- Compliance costs decreased to $362,172 in fiscal 2026 from $526,603 in fiscal 2025.
- The company has 31 appointed distributors globally, covering approximately 45 countries.
- Medinotec Group had 48 employees and independent contractors as of February 28, 2026.
- An impairment allowance was recorded against a $750,000 receivable from Innovative Outcomes.
Price Impact